ダウンロード数: 193
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
40_303.pdf | 380.33 kB | Adobe PDF | 見る/開く |
タイトル: | 進行性尿路上皮癌に対するM-VAC(methotrexate vinblastine,adriamycin and cisplatin)療法の治療成績 |
その他のタイトル: | Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer |
著者: | 三神, 一哉 中川, 修一 高田, 仁 戎井, 浩二 杉本, 浩造 渡辺, 泱 前川, 幹雄 中尾, 昌宏 |
著者名の別形: | Mikami, Kazuya Nakagawa, Shuichi Takada, Hitoshi Ebisui, Koji Sugimoto, Kozo Watanabe, Hiroki Maegawa, Mikio Nakao, Masahiro |
キーワード: | M-VAC chemotherapy (advanced) Urothelial cancer |
発行日: | Apr-1994 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 40 |
号: | 4 |
開始ページ: | 303 |
終了ページ: | 307 |
抄録: | 進行性尿路上皮癌27例に対してM-VAC療法を施行した。CR 2例(15.4%)を含め奏効率は, 44.4%と, 導入療法としては良好な成績であった。しかし, 再発および再燃が高率に認められ, 維持療法の確立が必要と考えられた M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy was performed on 27 patients with advanced urothelial cancer. The patients included 20 with bladder cancer, 4 with upper urinary tract cancer and 3 with both lesions. Complete response (CR) was observed in 2 (7.4 +/- 9.9%) patients and partial response (PR) in 10 (37.0 +/- 18.2%) patients after the treatment, i.e., the overall objective response rate was 44.4 +/- 18.7%. The rate of relapse or recurrence in the patients with CR and PR was 100% and 90.0%, respectively. The mean duration of the response was 18.5 +/- 13.4 months and 10.7 +/- 10.9 months for CR and PR, respectively. The overall survival rate after one year was 30.2%. Bone marrow suppression was the most serious side effect. The white blood cell count became below 1, 000/microliters in 10 patients (36.7%). Among them, 4 patients suffered from sepsis. In conclusion, M-VAC chemotherapy was effective for induction therapy against advanced urothelial cancer, although the effective duration was short. Further maintenance therapy should be established. |
URI: | http://hdl.handle.net/2433/115250 |
PubMed ID: | 8191968 |
出現コレクション: | Vol.40 No.4 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。